EasyCookieInfo

Harnessing the Immune System to fight Cancer and Infectious diseases


Takis main focus is the development of therapeutic cancer vaccines against tumor antigens which play a role in tumor development and maintenance.

February 3, 2021 - Takis and Rottapharm Biotech announce the authorization of the clinical trial by the Italian Medicines Agency (AIFA) of COVID-eVax

Trials to begin at the end of February

Takis and Rottapharm Biotech announce the authorization of the clinical trial by the Italian Medicines Agency (AIFA) of COVID-eVax, the vaccine against COVID-19 designed by Takis and developed in collaboration with Rottapharm Biotech.

To explore Takis opportunities, click here

Our team
is recognized

for the conception and implementation of a number of innovative technologies with the goal to improve in vivo gene transfer, regulation of gene expression and immunogenicity.

 

Takis as a CRO provides a variety of research services
 

in the areas of Oncology, Immunology, Infectious Diseases and novel preclinical models.

 
 

eit HEALTH - European Union

eit Health

Progetto di ricerca e sviluppo “Messa a punto di metodi di produzione e purificazione di vettori di espressione per uso clinico: AAV, HSV-1, MVA e DNA - VECTOPUR

Cofinanziamento dell’Unione Europea - FESR, PON Imprese e Competitività 2014-2020

CUP B88I17000100008

Progetto cofinanziato dall’Unione Europea, dallo Stato Italiano e dalla Regione Campania, nell’ambito del POR Campania FESR 2014 - 2020

Progetto "DALLA GENOMICA ALLA TERAPIA DI TUMORI RARI - CUP B61C17000060007"cofinanziato dall’Unione Europea, dallo Stato Italiano e dalla Regione Campania, nell’ambito del POR Campania FESR 2014 - 2020

Progetto cofinanziato dall’Unione Europea, dallo Stato Italiano e dalla Regione Campania, nell’ambito del POR Campania FESR 2014 - 2020
Takis Biotech

Harnessing the Immune System to fight cancer.

 
 
 
Takis S.r.l.

Via Castel Romano, 100
00128 Rome - Italy
P. I.V.A. 10700711004

 
 
Follow us